Frederick Lansigan, MD
Hematology & Oncology · Lebanon, NHNPI 1548436520
Payments from drug & device makers
Across 276 payments — averaging $2781.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$127K
- Otsuka Pharmaceutical Co., Ltd.$127K
- AbbVie$117K
- Morphosys AG$94K
- Regeneron$77K
- Janssen Research & Development, LLC$39K
- plus $188K from 18 others
Across 1 payment — averaging $3031.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 106 | $127,362 |
| Otsuka Pharmaceutical Co., Ltd. | 23 | $126,677 |
| AbbVie | 24 | $116,722 |
| Morphosys AG | 11 | $93,703 |
| Regeneron | 17 | $76,866 |
| Janssen Research & Development, LLC | 17 | $38,879 |
| Beigene USA, Inc. | 8 | $31,260 |
| Kyowa Kirin Pharmaceutical Development, Inc | 5 | $29,288 |
| Bristol Myers Squibb | 7 | $24,494 |
| Incyte Corporation | 13 | $23,866 |
| Innate Pharma, Inc | 1 | $19,264 |
| Epizyme, Inc. | 1 | $15,200 |
| Beigene, Ltd. | 4 | $12,560 |
| Beone Medicines Ltd. | 1 | $8,580 |
| E.r. Squibb & Sons, L.L.C. | 5 | $8,165 |
| Aurobindo Pharma USA, Inc. | 17 | $6,243 |
| Seagen Inc. | 7 | $6,015 |
| AstraZeneca | 2 | $2,000 |
| Gilead | 2 | $243 |
| Syndax Pharmaceuticals, Inc. | 1 | $116 |
| Kyowa Kirin, Inc. | 1 | $98 |
| Genmab U.S., Inc. | 1 | $74 |
| Blueprint Medicines Corporation | 1 | $23 |
| Pfizer | 1 | $20 |
How this compares
$767,717 in reported general payments places this provider in the 95th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Lebanon
- Konstantin DragnevLebanon$2.9M
- Keisuke ShiraiLebanon$917K
- Parth ShahLebanon$523K
- Gary SchwartzLebanon$355K
- Kathryn HourdequinLebanon$165K
- Kenneth MeehanLebanon$101K
- Sergey DevitskiyLebanon$58K
- Raphael LizcanoLebanon$39K
- John HillLebanon$31K
- Garrett WaspLebanon$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.